Syros Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SYRS)

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month target prices for Syros Pharmaceuticals' shares. Their SYRS share price targets range from $7.00 to $15.00. On average, they expect the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 363.0% from the stock's current price.
View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts.

Syros Pharmaceuticals' stock was trading at $3.59 at the start of the year. Since then, SYRS shares have decreased by 24.8% and is now trading at $2.70.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our SYRS earnings forecast.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its quarterly earnings results on Friday, November, 5th. The company reported ($4.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.40) by $0.30. The firm earned $5.70 million during the quarter, compared to the consensus estimate of $5.10 million. During the same period in the previous year, the company posted ($4.30) earnings per share.

Syros Pharmaceuticals's stock reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Avidity Partners Management LP (7.63%), CHI Advisors LLC (6.27%), LPL Financial LLC (0.44%), Assenagon Asset Management S.A. (0.12%), Clarius Group LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Roth, Eric R Olson, Richard A Young and Timothy Tyson.
View institutional ownership trends.

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.